Figure 6.

Abemaciclib treatment inhibits patient-derived ependymoma xenografts growth in vivo. (A,B) The third-generation xenografts were injected subcutaneously into the flank regions of nude mice, and abemaciclib was administered orally (50 mg/kg/day) five times per week. Tumor volume (A) and body weight (B) were recorded every 6 or 7 days. The figure shows the relative tumor volume and body weight compared with those at the first abemaciclib feeding. * p < 0.05, ** p < 0.01. (C) IHC staining for detection of Ki-67 and γH2AX expression and RB phosphorylation after abemaciclib treatment. Scale bar: 50 µm.